NDA 208325 · Kai Pharms INC
Parsabiv
Etelcalcetide · Intravenous
NovelLast checked: Nov 20, 2026Latest source record: Feb 11, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Feb 7, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
20
9 Phase 3, 2 recruiting
FAERS reports
2,877
1,403 serious, 335 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 8, 2026.
PARSABIV is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. PARSABIV is a calcium-sensing receptor agonist indicated for: Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. ( 1 ) Limitations of Use: PARSABIV has not been studied in adult patients with parathyroid carcinoma, primary hyperparathyroidism, or with CKD who are not on hemodialysis and is not recommended for use in these populations. Limitations of Use: PARSABIV has not been studied in adult patients with parathyroid carcinoma, primary hyperparathyroidism, or with chronic kidney disease who are not on hemodialysis and is not recommended for use in these populations .
Mechanism: Etelcalcetide is a calcimimetic agent that allosterically modulates the calcium-sensing receptor (CaSR). Etelcalcetide binds to the CaSR and enhances activation of the receptor by extracellular calcium. Activation of the CaSR on parathyroid chief cells decreases PTH secretion.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- PARSABIV · ETELCALCETIDE 5MG/ML (5MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- PARSABIV · ETELCALCETIDE 10MG/2ML (5MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- PARSABIV · ETELCALCETIDE 2.5MG/0.5ML (2.5MG/0.5ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Etelcalcetide" as an intervention, any sponsor and status, largest first.
- Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on HemodialysisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT02102204 · 902 participants · Start Mar 25, 2014 · Primary completion Nov 4, 2016
Drug: Etelcalcetide · For: Hyperparathyroidism, Secondary
Sites: Birmingham, Alabama; Alhambra, California; Azusa, California · 228 sites in all
- Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on HemodialysisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01785875 · 891 participants · Start Jul 31, 2013 · Primary completion Jul 1, 2015
Drug: Etelcalcetide · For: Hyperparathyroidism, Secondary
Sites: Birmingham, Alabama; Pine Bluff, Arkansas; Azusa, California · 208 sites in all
- Head-to-Head Study of Etelcalcetide (AMG 416) and CinacalcetPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01896232 · 683 participants · Start Aug 13, 2013 · Primary completion Nov 12, 2014
Drug: Etelcalcetide; Cinacalcet and 2 more · For: Secondary Hyperparathyroidism; Chronic Kidney Disease
Sites: Azusa, California; Bakersfield, California; Chula Vista, California · 182 sites in all
- Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT03299244 · 637 participants · Start May 15, 2018 · Primary completion Apr 8, 2020
Drug: Etelcalcetide; Cinacalcet · For: Secondary Hyperparathyroidism; Chronic Kidney Disease
Sites: Beijing, China; Lanzhou, China; Guangzhou, China · 90 sites in all
- Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on HemodialysisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01788046 · 515 participants · Start Mar 12, 2013 · Primary completion Apr 14, 2014
Drug: Etelcalcetide; Placebo · For: Hyperparathyroidism, Secondary
Sites: Mobile, Alabama; Azusa, California; Beverly Hills, California · 106 sites in all
- Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on HemodialysisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01785849 · 508 participants · Start Mar 12, 2013 · Primary completion May 22, 2014
Drug: Etelcalcetide; Placebo · For: Hyperparathyroidism, Secondary
Sites: Birmingham, Alabama; Pine Bluff, Arkansas; Azusa, California · 118 sites in all
- Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to EtelcalcetidePivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01932970 · 158 participants · Start Aug 12, 2013 · Primary completion Jan 14, 2014
Drug: Etelcalcetide · For: Hyperparathyroidism, Secondary
Sites: Alhambra, California; Azusa, California; Bakersfield, California · 40 sites in all
- MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney DiseasePivotal-lookingCompleted
Shaanxi Micot Pharmaceutical Technology Co., Ltd.Industry
NCT06690242 · 115 participants · Start Nov 4, 2024 · Primary completion Aug 30, 2025
Drug: MT1013; MT1013 and 2 more · For: Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Sites: Hangzhou, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- underdose247
- shunt stenosis204
- nausea192
- hypocalcaemia151
- product storage error149
- blood parathyroid hormone increased145
- shunt occlusion128
- blood calcium decreased124
- diarrhoea116
- vomiting107
- circumstance or information capable of leading to medication error82
- death82
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 2 |
| 2017 | 212 |
| 2018 | 918 |
| 2019 | 628 |
| 2020 | 378 |
| 2021 | 251 |
| 2022 | 208 |
| 2023 | 128 |
| 2024 | 81 |
| 2025 | 56 |
| 2026 | 15 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Block GA, Bushinsky DA, Cheng S, et al. · JAMA 2017 · Clinical Trial, Phase III, Multicenter Study
- Etelcalcetide Inhibits the Progression of Left Atrial Volume Index Compared to Alfacalcidol in Hemodialysis Patients.
Dörr K, Reindl-Schwaighofer R, Lorenz M, et al. · Cardiorenal Med 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies.
Nakai K, Kono K, Yamada S, et al. · Ther Apher Dial 2024 · Systematic Review, Meta-Analysis
- Randomized Trial of Etelcalcetide for Cardiac Hypertrophy in Hemodialysis.
Dörr K, Kammer M, Reindl-Schwaighofer R, et al. · Circ Res 2021 · Multicenter Study, Randomized Controlled Trial
- Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
Karaboyas A, Muenz D, Fuller DS, et al. · Am J Kidney Dis 2022 · Clinical Trial, Research Support, N.I.H., Extramural
- Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.
Chen P, Narayanan A, Wu B, et al. · Clin Pharmacokinet 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Kai Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.